FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT Trump Talks to 2 Silicon Valley Execs About FDA Roles
01/12/2017
 
 
TXT Trump’s HHS Pick Will Divest Pharma Stock Ownership
01/13/2017
 
 
TXT Alliance Sees Battles Ahead for FDA Funding
01/13/2017
 
 
TXT Price Intervened at FDA for Drug, Device Firms: Media Report
01/10/2017
 
 
TXT FDA Discussion Paper on New LDT Oversight Proposal
01/13/2017
 
 
TXT FDA Chooses Biologic Nonproprietary Suffix Format
01/12/2017
 
 
TXT FDA Guide on Multiple Endpoints in Clinical Trials
01/12/2017
 
 
TXT CBER ‘Enhanced Operational Efficiency’ in FY 2016: Marks
01/10/2017
 
 
TXT Latest FDA Warning Letters
01/17/2017
 
 
TXT Since Our Last Issue ...
01/16/2017
 
 
TXT Latest Federal Register Notices
01/16/2017
 
 
TXT Product Approval Summaries
01/16/2017
 
 
TXT ICH Proposes Revisions to Good Clinical Practice Guidelines
01/13/2017
 
 
TXT Draft Guide on Referencing Approved Products in ANDAs
01/13/2017
 
 
TXT Fujifilm Medical Removing Older Duodenoscopes from Market
01/13/2017
 
 
TXT Guidance on IDE Benefit-Risk Determinations
01/12/2017
 
 
TXT Draft Guide on Generic 180-day Exclusivity
01/12/2017
 
 
TXT FDA Issues 2 Drug Compounding Guidances
01/12/2017
 
 
TXT FDA, IBM Open Health Data Exchange Project
01/11/2017
 
 
TXT Industry May Prefer to Keep ‘Intended Use’ Rule
01/11/2017
 
 
TXT Biopharmaceutical Innovation ‘Robust’: QuintilesIMS Report
01/11/2017
 
 
TXT CDER Planning 101 Guidances This Year
01/11/2017
 
 
TXT Implantable Infusion Pump Concerns in MR Environment
01/11/2017
 
 
TXT Stakeholders Want FDA ‘Twitter’ Research Changed
01/10/2017
 
 
TXT Galena Updates Federal False Claims Act Probe
01/10/2017
 
 
TXT FDA Encouraging Clinical Trial Participation, Diversity
01/10/2017
 
 
TXT FDA Guide on Combination Product GMP Compliance
01/10/2017
 
 
TXT Drug Distributer Pleads Guilty in $100 Million Scheme
01/09/2017
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving